4 unknown, 3 completed, 2 recruiting, 2 terminated. 8 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Unknown 3, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Phase 3 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow mFOLFOX6 regimen: new trials by email Literature Review of mFOLFOX6 regimen trials Research Report on mFOLFOX6 regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer Camrelizumab, Trastuzumab, XELOX regimen - Colorectal Neoplasms, Intestinal Neoplasms | Phase 2 | Unknown | Fudan University | 77 | 2022-01-01 | 2022-01-14 |
| Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) MRTX849, Cetuximab, mFOLFOX6 Regimen - Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | Mirati Therapeutics Inc. | 461 | 2021-06-24 | 2026-09-28 |
| QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety QL1203, Placebo, mFOLFOX6 regimen - Metastatic Colorectal Cancer | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 590 | 2020-01-20 | 2023-05-26 |
| Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors Dalutrafusp alfa, mFOLFOX6 Regimen - Advanced Solid Tumors | Phase 1 | Terminated | Gilead Sciences | 22 | 2019-06-03 | 2023-11-21 |
| Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer Bevacizumab, mFOLFOX6 regimen, mOXXEL regimen - Ras-mutated Metastatic Colorectal Cancer | Phase 2 | Unknown | National Cancer Institute, Naples | 200 | 2019-05-24 | 2023-11-13 |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 Paclitaxel, mFOLFOX6 regimen - Gastric Cancer Stage IV, Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Completed | Seoul National University Bundang Hospital | 35 | 2018-12-24 | 2023-12-05 |
| FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer mFOLFOX6 regimen - Gastric Cancer, Effects of Chemotherapy | Phase 2 | Unknown | Peking Union Medical College Hospital | 75 | 2013-10-01 | 2014-08-27 |
| Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer ABT-869, bevacizumab, oxaliplatin - Advanced Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 159 | 2008-10-01 | 2013-05-15 |
| A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer sorafenib, bevacizumab, mFOLFOX6 regimen - Metastatic Colorectal Cancer | Phase 1 | Terminated | Accelerated Community Oncology Research Network | 8 | 2008-10-01 | 2011-11-02 |
Colorectal Neoplasms (6) · Rectal Neoplasms (5) · Colonic Neoplasms (2) · Stomach Neoplasms (2) · Carcinoma, Pancreatic Ductal (1) · Gastrointestinal Neoplasms (1) · Intestinal Neoplasms (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1)
Sixth Affiliated Hospital, Sun Yat-sen University (3) · AbbVie (prior sponsor, Abbott) (1) · Accelerated Community Oncology Research Network (1) · Fudan University (1) · Gilead Sciences (1) · Mirati Therapeutics Inc. (1) · National Cancer Institute, Naples (1) · Peking Union Medical College Hospital (1) · Qilu Pharmaceutical Co., Ltd. (1) · Revolution Medicines, Inc. (1) · Seoul National University Bundang Hospital (1)
China (7) · United States (5) · South Korea (3) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Czechia (2) · Greece (2) · Italy (2) · Poland (2) · Portugal (2) · Romania (2) · Spain (2) · Argentina (1)
Alfredo Budillon, MD (1) · Antonio Avallone, MD (1) · Fred Schnell, MD (1) · Guohui Wan, PhD. (1) · Hyung-Ho Kim, M.D., PhD. (1) · Juan Huang, PhD. (1) · Jun Huang, PhD (1) · Jun Huang, PhD. (1) · Lin Shen, Professor (1) · Maria Carmela Piccirillo, MD (1) · Mark D. McKee, MD (1) · Weijian Guo, Professor (1)
PMID 22189752, PMID 32849914, PMID 39752885, PMID 40056080
2018 (1), 2019 (1)